SCHEMBL20601280

SCHEMBL20601280

CCOC(=O)N1CCC(CC(NC(=O)c2ccc(F)cc2)c2ccc(OC)nc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 3/20 0.45
MAPT P10636 2/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.43
KCNH2 Q12809 2/20 0.42
MCHR1 Q99705 2/20 0.42
ALDH1A1 P00352 2/20 0.40
USP2 O75604 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 3/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20601320 0.94 KCNK3 (0.45) KCNK3KCNH2MCHR1MAPK1
SCHEMBL20601277 0.93 KCNK3 (0.43) KCNK3MAPTTSHRKCNH2MCHR1
SCHEMBL20601454 0.91 KCNK3 (0.44) KCNK3KCNH2MCHR1MAPK1
SCHEMBL23088072 0.90 KCNK3 (0.45) KCNK3KCNH2MCHR1ALDH1A1GAA
SCHEMBL20601515 0.90 KCNK3 (0.45) KCNK3KCNH2MCHR1ALDH1A1GAA
SCHEMBL20601460 0.90 GPR119 (0.48) KCNK3KCNH2MCHR1TP53MEN1
SCHEMBL20618534 0.90 GPR119 (0.48) KCNK3KCNH2MCHR1TP53MEN1
SCHEMBL20618538 0.90 GPR119 (0.48) KCNK3KCNH2MCHR1TP53MEN1
SCHEMBL20601214 0.84 TSHR (0.51) MAPTTSHRRAB9AALDH1A1LMNA
SCHEMBL20618533 0.83 KDM4E (0.42) TP53MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210078988-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-03-18 US disclosed
US-20210078988-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-03-18 US disclosed
EP-3645519-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GlaxoSmithKline Intellectual Property Development Limited (GB) 2020-05-06 EP disclosed
CN-110770222-A Modulators of indoleamine2, 3-dioxygenase 葛兰素史克知识产权开发有限公司 2020-02-07 CN disclosed
WO-2019003142-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed
WO-2019003142-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078988-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, TPH1 KCNK3 3113/4885MAPT 1969/4885TSHR 2782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.